Solid quarterly results for the diversified healthcare company contrasted with those of its larger rival, Johnson & Johnson
Abbott said it earned $1.44 billion, or 92 cents per share, with results tempered by costs of recent acquisitions. That compared with $1.54 billion, or 98 cents per share, a year earlier.
Excluding special items, earnings of $1.30 per share beat the analysts' average forecast of $1.29, according to Thomson Reuters I/B/E/S.
Sales of the suburban Chicago company rose 13.4 percent to $9.97 billion, helped by Abbott's recent purchase of Solvay SA's
Global pharmaceutical sales jumped almost 23 percent to $5.94 billion. Its flagship product, Humira for rheumatoid arthritis, rose 13 percent to $1.88 billion, while combined sales of its Trilipix and TriCor medicines to lower blood fats called triglycerides, rose 19 percent to $499 million.
Niaspan, which raises good HDL cholesterol, gained almost 13 percent to $286 million. Abbott's coronary stents, used to prop open arteries that have been cleared of plaque, remained a dependable growth driver -- with sales jumping almost 20 percent to $514 million.
But pediatric nutritionals remained a disappointment, falling nearly 6 percent to $742 million following a recall last September of the company's beetle-contaminated Similac infant formula
(Reporting by Ransdell Pierson; Editing by Lisa Von Ahn and Maureen Bavdek)